Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
As a long-term multiple myeloma survivor and MM coach I’m often asked about non-conventional (not FDA approved) multiple myeloma therapy. In the case of Fenbendazole, (the vet cure, vet medicine) several people have recently asked me about the possibility of a therapy given to animals being a multiple myeloma therapy.
No question is more conflicting for me. Despite the fact that my own oncologist told be that “we can do nothing more for you” and I achieved complete remission after 17 months taking an evidence-based, non-toxic, non-conventional multiple myeloma therapy, I have tried to walk the line between conventional MM oncology and evidence-based non-conventional MM oncology ever since the launch of PeopleBeatingCancer in June of 2004.
There is no question in my mind that conventional MM oncology with its
are central to the lives of MM patients, survivors and caregivers.
Yet my own history as a long-term multiple myeloma survivor is rife with examples of my own oncologists and M.D.’s placing my health and well-being behind their own priorities and interests.
Most importantly, by it’s own admission, conventional MM oncology cannot cure multiple myeloma. If the patient responds, multiple myeloma therapy, on average, will manage multiple myeloma for 3-5 years.
The average five year survival rate for newly diagnosed MM patients is 49%. Years of short, long-term and late stage side effects costing the MM patient hundreds of thousands of dollars will, on average, result in about five years of survival.
So if a newly diagnosed MM patient, a patient who has recently learned that he/she has an incurable cancer, sends me an email asking about a medicine usually given to animals to de-worm them, I have to do my darnedest to provide information about that non-conventional MM therapy.
The fact is, there are dozens of evidence-based, non-toxic multiple myeloma therapies. Conventional, board certified oncologists are not allowed to prescribe multiple myeloma therapy that is not approved by the FDA- by law. This is the way medicine works in the United States in 2020.
Have you been diagnosed with multiple myeloma? To learn more about the full spectrum of evidence-based multiple myeloma therapy, both conventional and non-conventional, scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
“Fenbendazole is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, and seals.
Fenbendazole is being investigated for use as a cancer treatment in humans.
“Benzimidazoles, including albendazole, fenbendazole, mebendazole, and nocodazole, have been used as anthelmintics and fungicides on the basis of their antimicrotubule activity (10) and have been reported to elicit promising antitumor effect (11–13)…
Nocodazole alone and in combination with dexamethasone inhibits multiple myeloma tumor growth in vitro and in vivo
To further investigate the effects of nocodazole, we tested nocodazole in combination with other compounds. As shown in Fig. 5A, combination of nocodazole with lenalidomide, dexamethasone, or a novel histone deacetylase inhibitor inhibitor KD5170 (17) resulted in a significant (P < 0.05) inhibition of proliferation compared with either drug alone…
In summary, our studies show that nocodazole targets the multiple myeloma cell and its microenvironment (14). Nocodazole mediates its antimyeloma activity through sequential microtubular network damage and cell-cycle arrest. JNK-mediated Bcl-2 phosphorylation results in multiple myeloma cell apoptosis. Nocodazole overcomes drug resistance, decreases tumor growth, and extends survival in vivo in human xenograft mice model. The known toxicity profile and selective activity against myeloma cells provide the rationale for considering nocodazole as future treatment for multiple myeloma.”
“This study demonstrated that a combination of supplemented vitamins and fenbendazole in the diet inhibited growth of a human lymphoma cell line in SCID mice, whereas fenbendazole or vitamins alone had no growth inhibitory effect…
Our study showed that fenbendazole alone did not significantly affect growth of the P493-6 human lymphoma cell line in SCID mice. Most importantly, our observation that fenbendazole in combination with supplemented vitamins significantly inhibited tumor growth has implications for its use during antitumor studies because it may cause unpredictable interactions with test substances and thus alter research results…”
“Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer, and despite treatment advances, patient prognosis remains poor. During routine animal studies, we serendipitously observed that fenbendazole, a benzimidazole antihelminthic used to treat pinworm infection, inhibited brain tumor engraftment…
In summary, MBZ offers a highly promising opportunity for clinical application on GBM. This is because it has a long track record of safety, there is evidence of preclinical efficacy, an anti-cancer mechanism has been revealed, cost is relatively low, the drug widely available as a generic drug, there is good CNS penetration, and there is a great need for better GBM therapy…”